Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and forth in a narrow range before ending higher.

The recent FDA decision will reverberate across the industry and the healthcare sector for many reasons.